All oral contraceptive (OC) orders will consist of 3 cycles.
Free shipping on all orders!
*min order 3 cycles
Upon checkout, your order will be reviewed by a licensed U.S. physician. Once our physician has approved your Junel® FE 1/20 order, your payment will be processed. We’ll ship your Junel® FE in discreet and confidential packaging via USPS First Class Mail.
Junel® FE 1/20
(Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets, 1mg/20mcg/75mg)
Junel® FE 1/20 is approved as an AB –Rated generic oral contraceptive with a reference drug of Loestrin® FE 1/20 Tablets. Junel® FE 1/20 compares to Gildess® FE 1/20, Tarina® FE 1/20, Larin® FE 1/20, Microgestin® FE 1/20.
Junel® FE 1/20 is a combination oral contraceptive, meaning it contains a combination of the two female sex hormones estrogen and progestin. Junel® FE 1/20 is indicated for pregnancy prevention among women who choose to use oral contraceptives for contraception. This progestogen-estrogen combo pill helps prevent pregnancy in two main ways. First, the hormones help thicken the vaginal mucus, making it more difficult for sperm to travel toward an egg. If fertilization does occur, the second change Junel® FE 1/20 makes to the body acts as a backup. The uterine lining (where the fertilized egg would normally implant) becomes thick and difficult for implantation to occur.
Combination birth control pills like Junel® FE 1/20 also cause ovulation to cease. When this happens, an egg is no longer present for fertilization.
IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE OF JUNEL FE 1/20®
June Fe 1/20 is a combined oral contraceptive (COC) indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
SELECTED SAFETY INFORMATION
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
BRIEF SUMMARY: CONSULT THE PACKAGE INSERT FOR COMPLETE PRESCRIBING INFORMATION
Combined oral contraceptives (COC's), including June Fe 1/20, should not be used in women with any of the following conditions:
- Thrombophlebitis or thromboembolic disorders
- A past history of deep vein thrombophlebitis or thromboembolic disorders
- Cerebral vascular or coronary artery disease
- Known or suspected carcinoma of the breast
- Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
- Undiagnosed abnormal genital bleeding
- Cholestatic jaundice of pregnancy or jaundice with prior pill use
- Hepatic adenomas or carcinomas
- Known or suspected pregnanc
WARNINGS AND PRECAUTIONS
- Thrombotic and other vascular events- Stop June Fe 1/20 if an arterial or venous thrombotic event occurs, 4 weeks before and 2 weeks after major surgeries or surgeries known to have an elevated risk of thromboembolism, or if there is an unexplained loss or change of vision (Evaluate for retinal thrombosis immediately.). Combined oral contraceptives should be used with caution in women with cardiovascular risk factors.
- Carcinoma of the breast- Women with current or past history of breast cancer should not use June Fe 1/20.
- Liver Disease- Discontinue June Fe 1/20 if jaundice develops. Hepatic adenomas and very rare hepatocellular carcinoma (> 8 years use) are associated with COC use.
- High Blood pressure- Women with well-controlled hypertension should be monitored closely. Women with uncontrolled hypertension should not use June Fe 1/20.
- Other warnings and precautions include gall bladder disease, carbohydrate and lipid metabolic effects, headache, bleeding irregularities including amenorrhea, COC use before and during pregnancy, depression, and interference with laboratory tests.
ADVERSE REACTIONS / SIDE EFFECTS
The most serious reactions are discussed above and include serious cardiovascular events and smoking, vascular events and liver disease. Commonly reported adverse reactions include irregular uterine bleeding, nausea, breast tenderness and headache.
Patients should be counseled that June Fe 1/20 does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Please see full prescribing information here.
To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.